| 0.0006 0 (0%) | 04-17 15:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.02 |
1-year : | 0.03 |
| Resists | First : | 0.02 |
Second : | 0.02 |
| Pivot price | 0.02 | |||
| Supports | First : | 0.01 |
Second : | 0.01 |
| MAs | MA(5) : | 0.02 |
MA(20) : | 0.02 |
| MA(100) : | 0.03 |
MA(250) : | 0.12 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 41.5 |
D(3) : | 37.3 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 0.31 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STAB ] has closed above bottom band by 32.9%. Bollinger Bands are 82.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 74 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.02 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
Wed, 15 Mar 2023
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs - Yahoo Finance
Thu, 06 Oct 2022
What Is Going on With Statera (STAB) Stock Today? - InvestorPlace
Sun, 11 Sep 2022
Statera Biopharma faces involuntary bankruptcy petition - Loveland Reporter-Herald
Thu, 21 Apr 2022
Coeptis Therapeutics Inc (OTCMKTS: COEP) and Statera Biopharma Inc (NASDAQ: STAB) Make a Deal - BP Journal
Wed, 13 Apr 2022
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod ... - PR Newswire
Mon, 20 Dec 2021
FDA Lifts Clinical Hold On Statera Biopharma Inc.'s (NASDAQ: STAB) Entolimod Study In Acute Radiation Syndrome - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 775 (K) |
| Shares Short P.Month | 829 (K) |
| EPS | -2.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | 0 % |
| Operating Margin | -573.3 % |
| Return on Assets (ttm) | -23.9 % |
| Return on Equity (ttm) | -287 % |
| Qtrly Rev. Growth | 183.5 % |
| Gross Profit (p.s.) | 0.01 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.1 |
| Price to Sales | 0.38 |
| Price to Cash Flow | -0.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|